Aethlon Medical, Inc. Stock News

SAN DIEGO , Oct. 8, 2024 /PRNewswire/ -- Aethlon Medical, Inc.  (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that James Frakes, Chief Executive Officer and Chief Financial Officer, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit, hosted by Anthony Vendetti, e...

Aethlon Medical Granted Full Ethics Approval from the Medanta Institutional Ethics Committee for a Safety, Feasibility, and Dose Finding Study of its Hemopurifier® in Cancer Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies SAN DIEGO , Sept. 19, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer...

SAN DIEGO , Sept. 17, 2024 /PRNewswire/ -- Aethlon Medical, Inc.  (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that management will present at the following virtual investor conferences in September: September 19-20: Life Sciences Investor Forum: James Frakes, Interim Chief Executive Office...

Aethlon's Trial is a Safety, Feasibility, and Dose Finding Study of the Hemopurifier® in Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies SAN DIEGO , Sept. 16, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that the Cancer Clinical T...

Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com

Results Support Future Study of the Hemopurifier® as Part of a Machine Perfusion Circuit to Further Assess its Association with Function of Retrieved Kidneys SAN DIEGO , Aug. 27, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced the publication in prepr...

Aethlon Medical, Inc. (NASDAQ:AEMD ) Q1 2025 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Michael Miller - Investor Relations, Rx Communications James Frakes - Interim Chief Executive Officer & Chief Financial Officer Steven LaRosa - Chief Medical Officer Conference Call Participants Marla Marin - Zacks Operator Good day, and welcome to the Aethlon Medical Fiscal Fir...

Received Two Australian Ethics Committee Approvals for a Safety, Feasibility, and Dose Finding Study of Aethlon's Hemopurifier® in Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies; Expects to Open Patient Enrollment in October of 2024 Achieved Significant 24% Reduction in Fiscal First Quarter Operating Expenses Compared to the Same Period in 2023 Conference Call to be Held Toda...